Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Betsy Hirsch

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Pediatric Blood & Cancer|September 2, 2021
Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology GroupKelly D Getz, Todd A Alonzo, Lillian Sung, et al.
Blood|December 25, 2007
Genetic endothelial systems biology of sickle stroke riskLiming Chang Milbauer, Peng Wei, Judy Enenstein, et al.
Cancer Genetics|July 12, 2015
Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology GroupMarijana Vujkovic, Edward F Attiyeh, Rhonda E Ries, et al.
Blood|March 24, 2009
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupPhoenix A Ho, Todd A Alonzo, Robert B Gerbing, et al.
Blood|April 24, 2010
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupPhoenix A Ho, Rong Zeng, Todd A Alonzo, et al.
Haematologica|February 8, 2020
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology GroupRichard Aplenc, Soheil Meshinchi, Lillian Sung, et al.
Pediatric Blood & Cancer|June 18, 2011
A phase II study of amifostine in children with myelodysplastic syndrome: a report from the Children's Oncology Group study (AAML0121)Prasad Mathew, Robert Gerbing, Todd A Alonzo, et al.
Cancer|July 19, 2011
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology GroupTodd M Cooper, Janet Franklin, Robert B Gerbing, et al.
Blood|April 16, 2017
Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group reportMarijana Vujkovic, Edward F Attiyeh, Rhonda E Ries, et al.
American Journal of Human Genetics|April 17, 2007
Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated with cognitive and behavioral abnormalitiesJorune Balciuniene, Ningping Feng, Kelly Iyadurai, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Pediatric Blood & Cancer|September 2, 2021
Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology GroupKelly D Getz, Todd A Alonzo, Lillian Sung, et al.
Blood|December 25, 2007
Genetic endothelial systems biology of sickle stroke riskLiming Chang Milbauer, Peng Wei, Judy Enenstein, et al.
Cancer Genetics|July 12, 2015
Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology GroupMarijana Vujkovic, Edward F Attiyeh, Rhonda E Ries, et al.
Blood|March 24, 2009
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupPhoenix A Ho, Todd A Alonzo, Robert B Gerbing, et al.
Blood|April 24, 2010
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupPhoenix A Ho, Rong Zeng, Todd A Alonzo, et al.
Haematologica|February 8, 2020
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology GroupRichard Aplenc, Soheil Meshinchi, Lillian Sung, et al.
Pediatric Blood & Cancer|June 18, 2011
A phase II study of amifostine in children with myelodysplastic syndrome: a report from the Children's Oncology Group study (AAML0121)Prasad Mathew, Robert Gerbing, Todd A Alonzo, et al.
Cancer|July 19, 2011
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology GroupTodd M Cooper, Janet Franklin, Robert B Gerbing, et al.
Blood|April 16, 2017
Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group reportMarijana Vujkovic, Edward F Attiyeh, Rhonda E Ries, et al.
American Journal of Human Genetics|April 17, 2007
Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated with cognitive and behavioral abnormalitiesJorune Balciuniene, Ningping Feng, Kelly Iyadurai, et al.
Pageof 7